Cartesian Therapeutics (RNAC) Revenue (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Revenue for 12 consecutive years, with $78000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Revenue fell 92.91% year-over-year to $78000.0; the TTM figure through Mar 2026 stood at $1.0 million (down 96.94% YoY), while the FY2025 annual figure was $2.8 million, down 92.69% from the prior year.
• Revenue fell to $78000.0 in Q1 2026 per RNAC's latest filing, from $947000.0 in the prior quarter.
• Across five years, Revenue topped out at $39.3 million in Q2 2022 and bottomed at -$836000.0 in Q4 2024.
• Historically, Revenue has averaged $12.7 million across 5 years, with a median of $6.2 million in 2023.
• On a YoY basis, Revenue climbed as much as 533.85% in 2024 and fell as far as 110.11% in 2024.
• Cartesian Therapeutics' Revenue stood at $16.8 million in 2022, then plunged by 50.78% to $8.3 million in 2023, then sank by 110.11% to -$836000.0 in 2024, then soared by 213.28% to $947000.0 in 2025, then slumped by 91.76% to $78000.0 in 2026.
• Business Quant data shows RNAC's Revenue at $78000.0 in Q1 2026, $947000.0 in Q4 2025, and $1.1 million in Q1 2025.